Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.

Leica Biosystems introduces the Novocastra™ HD menu for dermatopathology, the third portfolio of antibodies for IHC in the new Novocastra HD range.

Published: 06.03.13

6th March 2013

Place: Newcastle-upon-Tyne, UK.

 

Leica Biosystems introduces the Novocastra™ HD menu for dermatopathology, the third portfolio of antibodies for IHC in the new Novocastra HD range.

 

Each antibody has been independently assessed* for performance vs. their competitive offerings in the market, thereby enabling confidence in the interpretation of stained slides. The BOND™ Ready-to-Use products are optimized to deliver high quality staining on the Leica BOND immunostainer.  Products are available in a range of formats to align with customer requirements for efficiency and convenience.

 

Dr Robb E. Wilentz of Skin and Cancer Associates, Aventura, FL commented, “Leica has a wide variety of reliable antibodies covering the antigens routinely studied in our field of dermatopathology. Together with the BOND immunohistochemistry platform, this enables us to provide our clients with consistent, accurate and timely results. We are happy to have incorporated Leica's systems and dermatology antibodies into our daily routine."

 

The new Novocastra HD menu for dermatopathology comprises twelve** antibodies and will be available for sale in the USA, Canada and the EU from March 2013. Availabillity in other regions will follow.  Full details can be found at www.LeicaBiosystems.com/NovocastraHD.

 

Many BOND Ready-to-Use antibodies come in two sizes: 7 mL and a new 30 mL size for higher usage requirements.  Liquid concentrates are available in an expanded range of sizes from 0.1 mL to 1 mL. 

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting.

 

The company is represented in over 100 countries. It has manufacturing facilities in 6 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at www.LeicaBiosystems.com

 

For more information contact:

Tim Lyons

Global Marketing Communications Director

Leica Biosystems

1700 Leider Lane

Buffalo Grove, IL

USA

Telephone: + 1 847 405 5455

Mobile: +1 847 5010768

Email: tim.lyons@LeicaBiosystems.com

www.LeicaBiosystems.com

Human melanoma stained with Novocastra HD Melanoma Marker antibody, clone HMB45